Table. Out-of-Pocket Cost Savings for Select Generic Prescription Drugs Among Beneficiaries With Any Savings.
| Druga | Prescriptions (weighted), No.a | Proportion of prescriptions with savings, % (95% CI) | Cost savings by insurance type, median (IQR), 2023 $b | |||
|---|---|---|---|---|---|---|
| Medicare | Military | Private | Uninsured | |||
| Atorvastatin | ||||||
| 30 Pills | 35 118 775 | 7.91 (7.00-8.82) | 15.14 (1.50-17.74) | 0 | 4.06 (2.93-4.72) | 8.74 (1.86-8.74) |
| 90 Pills | 51 836 694 | 12.59 (11.66-13.51) | 4.10 (2.94-6.07) | 3.90 (3.90-3.90) | 1.89 (0.44-4.57) | 6.07 (1.47-7.55) |
| Amlodipine | ||||||
| 30 Pills | 27 397 161 | 6.31 (5.41-7.22) | 3.14 (3.14-8.39) | 4.14 (4.14-4.14) | 1.30 (1.30-1.30) | 6.25 (4.92-6.25) |
| 90 Pills | 38 911 361 | 13.34 (12.27-14.40) | 1.97 (1.54-2.94) | 5.05 (5.05-5.16) | 3.79 (2.94-6.03) | 97.24 (0.10-97.24) |
| Losartan | ||||||
| 30 Pills | 16 284 558 | 18.28 (16.34-20.22) | 3.4 (3.4-9.07) | 4.58 (4.58-4.58) | 3.4 (2.11-3.4) | 10.14 (10.14-10.14) |
| 90 Pills | 28 837 171 | 21.81 (20.28-23.34) | 5.61 (1.89-6.73) | 5.94 (0.36-5.94) | 2.35 (1.92-6.70) | 6.78 (3.05-21.83) |
| Fluoxetine | ||||||
| 30 Pills | 23 490 172 | 5.85 (4.80-6.90) | 0.55 (0.55-0.55) | 0 | 5.43 (0.55-5.43) | 0 |
| 90 Pills | 11 755 483 | 10.81 (8.90-12.72) | 0.92 (0.25-17.66) | 3.03 (3.03-3.03) | 5.95 (3.03-17.66) | 20.62 (20.62-20.62) |
| Simvastatin | ||||||
| 30 Pills | 10 956 492 | 13.30 (11.19-15.40) | 0.37 (0.37-0.37) | 0 | 4.20 (2.74-4.20) | 1.46 (1.46-1.46) |
| 90 Pills | 22 689 787 | 21.09 (19.38-22.79) | 3.62 (1.60-8.50) | 6.76 (6.76-6.76) | 1.80 (0.94-4.42) | 1.80 (1.80-1.80) |
| Rosuvastatin | ||||||
| 30 Pills | 8 917 136 | 14.80 (12.36-17.25) | 3.31 (2.51-3.34) | 0 | 2.71 (1.76-3.69) | 0.98 (0.98-0.98) |
| 90 Pills | 14 990 233 | 15.24 (13.35-17.13) | 8.29 (2.52-17.78) | 0 | 3.12 (1.97-5.37) | 0.22 (0.22-0.22) |
a
The drugs listed were chosen based on the most frequently available prescriptions.
b
Savings in 2023 US dollars were determined by subtracting the Mark Cuban Cost Plus Drug Company price (as of March 2023) from the adjusted out-of-pocket payment listed in the Medical Expenditure Panel Survey (MEPS) per prescription. The median (IQR) adjustment in out-of-pocket costs in MEPS was −12% (−34% to 3%) based on changes in the National Average Drug Acquisition Cost between 2019 and 2023.